China is pushing germline editing research – won’t stop – and other countries are following.
WESLEY W. CHEN June 30 2019 HUMAN GERMLINE GENE EDITING: ENGINEERING AN UNSTOPPABLE TRAIN https://mylaw2.usc.edu/why/students/orgs/ilj/assets/docs/28-2-Chen.pdf
No country is pushing human germline gene editing research harder than China. It is fitting that the country that first broke the glass door on gene editing in human embryos would be leading the way for the controversial field. Human germline editing research has been able to thrive in China in part because of how ethical research laws are (or better yet) not enforced. For example, in 2015, when China reported the first case of human germline editing, its Guidelines on Human Assisted Reproductive Technologies stated that “using human egg plasma and nuclear transfer technology for the purpose of reproduction, and manipulation of the genes in human gametes, zygotes or embryos for the purposes of reproduction are prohibited.” 99 However, the 2015 study was likely able to proceed because such administrative research guidelines are considered “soft law” and not thoroughly enforced.100 Today, any Chinese university or hospital can freely conduct clinical trials for gene editing technology with approval from their own ethics commissions and do not require approval by China’s federal government.101 Interestingly, it also seems that China is equally willing to support gene editing research for fixing disorders as opposed to human augmentation. For example, while one Chinese study gene edited embryos to correct the mutation for β-thalassemia,102 another Chinese study enhanced an embryo to give it genetic resistance against HIV.103 With other countries following China’s lead, one wonders whether it is inevitable that the United States will eventually join the fray.